On September 22, 2015, Governor Jerry Brown signed Assembly Bill 2, which will allow local governments to create Community Revitalization and Investment Authorities (CRIAs) -- a step some say is the ...
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) LAUSANNE, Switzerland and SHANGHAI, China, ...
Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company ...
Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 million biobucks deal for AB2 Bio’s late-stage autoimmune disease therapy.
Swiss orphan biotech AB2 Bio Ltd. has completed enrollment in a pivotal phase III trial for its recombinant interleukin-18-binding protein drug tadekinig alfa for an inherited form of the ultra-rare ...
Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio's Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...
AB2 Bio, a Swiss clinical-stage biotech company developing therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics agreed to collaborate to set up and accelerate ...
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake ...
AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain exclusive rights to commercialise Tadekinig alfa in the US. This therapy treats a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback